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Background: The MiStent is a new drug-eluting stent characterized by the use of crystalline sirolimus and a fully absorbable PLGA polymer on a 
thin-strut (64 µm) cobalt-chromium stent. Prior preclinical studies showed the stent coating being eliminated in 45-60 days with full absorption of 
the polymer by 90 days. This clinical IVUS study aimed to assess serial arterial response to this novel sirolimus-eluting stent (SES) in human coronary 
lesions.
methods: DESSOLVE-I First-In-Human Trial enrolled 30 patients with IVUS at baseline, mid-term (4, 6, or 8 months: 10 patients each) and long-
term follow-up (18 months). Neointimal obstruction was calculated as neointimal volume/stent volume (%). The neointimal roughness was evaluated 
by standard deviation of neointimal thickness along the entire stented segment.
results: Progressive increases in neointimal obstruction and roughness were observed up to 8 months, followed by no further progression observed 
at 18 months. While 70.6% of patients showed mild positive remodeling at mid-term, the peri-stent plaque volume returned to the baseline level by 
18 months. Late-acquired incomplete stent apposition was detected only in 2 cases at mid-term, one of which showed complete resolution at 18 
months.
conclusion: In the final IVUS results from DESSOLVE-I, the novel SES with absorbable polymer demonstrated significant neointimal suppression, 
associated with no late catch-up of in-stent neointima and favorable peri-stent arterial response at 18 months. 
